Literature DB >> 9665297

Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease.

J Macías1, J A Pineda, M Leal, M A Abad, F García-Pesquera, J Delgado, J A Gallardo, A Sánchez-Quijano, E Lissen.   

Abstract

The aims of this study were to analyze the mortality directly attributable to chronic viral hepatitis in HIV-1 infected patients and to investigate the influence of hepatitis virus infections on the survival of this population. A cohort of 328 HIV-1 infected, antiretroviral-treated patients, followed up from 1989 to 1996, was investigated in the study. The median follow-up period of the cohort was 120 weeks. The median baseline CD4 + cell count of the cohort was 303 cells/mm3. Hepatitis C virus, hepatitis B virus and hepatitis D virus infections were present in 214 (65%), 16 (4.9%) and 9 (2.7%) patients, respectively. Sixty-seven (20.4%) subjects died but there was no information on the vital status of 36 patients (11%). The causes of mortality were AIDS in 49 (73%), liver failure in 3 (4.5%) and other causes in 15 (22.4%). The cohort was divided into two groups for survival analysis, the groups consisting of persons infected by a hepatitis virus and persons without hepatitis virus infection. There was no difference in survival between the two groups (p = 0.31, log-rank). It is concluded that mortality among HIV-1/hepatitis virus coinfected patients with moderate to severe immunosuppression is mostly due to AIDS, and that the survival of these subjects is not influenced by the presence of hepatitis virus infections, particularly hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665297     DOI: 10.1007/bf01691112

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

Authors:  A Sánchez-Quijano; J Andreu; F Gavilán; F Luque; M A Abad; B Soto; J Muñoz; J M Aznar; M Leal; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

Review 2.  HIV viral load markers in clinical practice.

Authors:  M S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; D M Jacobsen; G M Shaw; D D Richman; P A Volberding
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

3.  Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.

Authors:  B Soto; A Sánchez-Quijano; L Rodrigo; J A del Olmo; M García-Bengoechea; J Hernández-Quero; C Rey; M A Abad; M Rodríguez; M Sales Gilabert; F González; P Mirón; A Caruz; F Relimpio; R Torronteras; M Leal; E Lissen
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

4.  [Mortality from chronic liver disease in patients with HIV infection].

Authors:  R Jover; A Gutiérrez; V Boix; J Portilla
Journal:  Med Clin (Barc)       Date:  1995-06-03       Impact factor: 1.725

5.  High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain.

Authors:  V Soriano; J García-Samaniego; M Gutiérrez; R Bravo; J Gonzalez-Lahoz
Journal:  J Infect       Date:  1994-01       Impact factor: 6.072

6.  Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group.

Authors:  V Soriano; J García-Samaniego; R Bravo; A Castro; P M Odriozola; J González; M Colmenero; E Carballo; D Suárez; J M Llibre
Journal:  J Infect       Date:  1995-07       Impact factor: 6.072

7.  Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

Authors:  L B Seeff; Z Buskell-Bales; E C Wright; S J Durako; H J Alter; F L Iber; F B Hollinger; G Gitnick; R G Knodell; R P Perrillo
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

Review 8.  Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses.

Authors:  J Horvath; S P Raffanti
Journal:  Clin Infect Dis       Date:  1994-03       Impact factor: 9.079

9.  High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV.

Authors:  B Cribier; D Rey; C Schmitt; J M Lang; A Kirn; F Stoll-Keller
Journal:  AIDS       Date:  1995-10       Impact factor: 4.177

10.  Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C.

Authors:  M E Eyster; J C Sanders; M Battegay; A M Di Bisceglie
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

View more
  11 in total

1.  Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.

Authors:  J Macías; J A Girón-González; M González-Serrano; D Merino; P Cano; J A Mira; A Arizcorreta-Yarza; J Ruíz-Morales; J M Lomas-Cabeza; J A García-García; J E Corzo; J A Pineda
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

2.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

3.  Impact of hepatitis C on HIV progression in adults with alcohol problems.

Authors:  Debbie M Cheng; David Nunes; Howard Libman; John Vidaver; Julie K Alperen; Richard Saitz; Jeffrey H Samet
Journal:  Alcohol Clin Exp Res       Date:  2007-03-31       Impact factor: 3.455

4.  Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.

Authors:  Lena Al-Harthi; John Voris; Wenbo Du; David Wright; Marek Nowicki; Toni Frederick; Alan Landay; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-03-17       Impact factor: 5.226

5.  Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.

Authors:  J Macías; J A Pineda; F Lozano; J E Corzo; A Ramos; E León; J A García-García; J Fernández-Rivera; J A Mira; J Gómez-Mateos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-23       Impact factor: 3.267

6.  Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.

Authors:  Ting-Yi Chen; Eric L Ding; George R Seage Iii; Arthur Y Kim
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

7.  Morbidity and mortality profile of human immunodeficiency virus-infected patients with and without hepatitis C co-infection.

Authors:  Angel M Mayor; Maria A Gomez; Diana M Fernandez; Eddy Rios-Olivares; James C Thomas; Robert F Hunter
Journal:  Am J Trop Med Hyg       Date:  2006-02       Impact factor: 2.345

8.  HIV and Hepatitis Virus Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.663

9.  Survival of HIV-positive individuals with hepatitis B and C infection in Michigan.

Authors:  Z A Butt; M J Wilkins; E Hamilton; D Todem; J C Gardiner; M Saeed
Journal:  Epidemiol Infect       Date:  2013-11-29       Impact factor: 4.434

10.  Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease.

Authors:  M Santin; M Mestre; E Shaw; M J Barbera; A Casanova; J Niubo; F Bolao; D Podzamczer; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.